We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 131

Third Circuit remands class certification ruling in blood reagents price-fixing case
  • McDermott Will & Emery
  • USA
  • April 15 2015

On Wednesday, April 8, 2015, the Third Circuit Court of Appeals vacated a district court’s order certifying a class of direct purchasers of blood


Third Circuit extends Actavis to reverse settlement agreements involving non-cash consideration
  • McDermott Will & Emery
  • USA
  • July 29 2015

Addressing for the first time whether reverse settlement agreements involving non-cash consideration merit antitrust scrutiny, the U.S. Court of


Allegations of antitrust and patent misuse surviving a motion to dismiss
  • McDermott Will & Emery
  • USA
  • October 30 2015

The U.S. District Court for the District of New Jersey was tasked with determining whether allegations in Defendants’ antitrust and patent misuse


AstraZeneca and Ranbaxy avoid heartburn of a new antitrust trial
  • McDermott Will & Emery
  • USA
  • October 30 2015

On August 7, 2015, Judge William G. Young, of the U.S. District Court for the District of Massachusetts, denied Plaintiffs’ post-trial motions


Reverse payment settlements subject to antitrust challenge
  • McDermott Will & Emery
  • USA
  • July 30 2015

In a class action case assessing the implications of antitrust law in a patent infringement and validity settlement agreement, the Supreme Court of


Split decisions regarding class certification in provigil antitrust lawsuits
  • McDermott Will & Emery
  • USA
  • October 30 2015

In two antitrust class actions in the U.S. District Court for the Eastern District of Pennsylvania, the court denied class certification as to


‘Sham litigation’ sufficiently plead when generic provides detailed statement and access to ANDA
  • McDermott Will & Emery
  • USA
  • October 30 2015

Explaining the differences between the pleading standards for antitrust and patent misuse defenses, the U.S. District Court for the District of New


A no-AG settlement agreement is subject to Actavis’ rule of reason analysis
  • McDermott Will & Emery
  • USA
  • October 30 2015

Plaintiffs, direct purchasers of the brand-name drug Lamictal (lamotrigine), sued Lamictal’s producer, SmithKline Beecham Corporation (SmithKline


When Customer Supply Contracts Lead to Trouble: Exclusive Dealing Provisions Result in FTC Monopolization Action against Invibio
  • McDermott Will & Emery
  • USA
  • May 4 2016

The Federal Trade Commission (FTC) continues to aggressively enforce the antitrust laws. On April 27, 2016, the FTC took action against Victrex, plc


European Court of Justice Rules that a Scottish Law Establishing Minimum Unit Pricing for Alcoholic Drinks May Violate EU Law
  • McDermott Will & Emery
  • European Union
  • December 29 2015

On 23 December 2015, the Court of Justice of the European Union (ECJ) - Europe's highest court - ruled that a Scottish law establishing minimum unit